Skip to main content

Monkeypox

Below is an overview of various sections of The Swedish COVID-19 & Pandemic Preparedness Portal where information about research data and resources relevant to Monkeypox can be found. For a short background on this topic below, see the description below.

Open funding opportunities (2)

Call title Deadline Funder Topics
The overall objective of the call is to support and accelerate cutting edge Nordic research with high potential for renewal and impact on the welfare among children and young people in the …
December 8, 2022 Swedish Research Council COVID-19General
Since early May, there has been a sudden and unexpected multi-country increase in monkeypox virus (MPXV) infections. Based on the outcomes of this consultation and the need for an immediate …
November 29, 2022 ISIDORe Infectious diseasesMonkeypox
    This page is under development, with more resources being added shortly. In the meantime, check out the monkeypox page in our 'emerging pathogens' section. That page contains more extensive information and useful links to other related resources.

For a fuller overview, refer to the monkeypox page of our emerging pathogens section.

Background

Monkeypox is caused by the monkeypox virus, and is a zoonotic disease (i.e. it is transmitted from animals to humans). The monkeypox virus is a member of the Orthopoxvirus genus in the family Poxviridae. It is closely related to the variola virus, which causes smallpox and has had a marked impact on human populations throughout history. According to WHO there are currently two clades of monkeypox virus; the West African clade and the Congo Basin (Central African) clade. An outbreak began in Europe during May 2022. As of Septmber 2022, more than 20,000 cases have been detected in Europe, with 161 cases detected in Sweden and reported to the Swedish Public Health Agency.

Clinically, monkeypox is typically characterised by fever, an unexplained acute rash, and lymphadenopathy. Additional symptoms and complications may also occur, though. For more information about the clinical symptoms of monkeypox, see information from the CDC. The incubation period of the virus is typically 5-13 days, but can be as long as three weeks. Close personal contact with an infected individual is currently (September, 2022) the most common way of transmission and limited information is available regarding mortality (Adler et al., 2022). The European Medicines Agency has not yet approved a vaccine in Europe. However, EU healthcare has access to doses of Jynneos vaccine, which is approved by the FDA for both monkeypox and smallpox. These vaccine doses were donated by the USA and Canada via the European Health Emergency Preparedness and Response Authority (HERA).

There are no approved treatments for human monkeypox as of September 2022. However, brincidofovir and tecovirimat, which are both drugs approved in the USA for use against smallpox, have been repurposed and show promise in animal studies (Adler et al., 2022).